Tamoxifen promotes differentiation of oligodendrocyte progenitors in vitro

Neuroscience

Volumn 319, Issue , 2016, Pages 146-154

  Barratt, H E ^a   Budnick, H C ^a   Parra, R ^a   Lolley, R J ^a   Perry, C N ^a   Nesic, O ^a,b  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

Author keywords

4 hydroxy tamoxifen; Astrocytes; Endoxifen; Estrogen receptors; Oligodendrocyte progenitors; Tamoxifen

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; 4 HYDROXY TAMOXIFEN; DRUG METABOLITE; ENDOXIFEN; ESTROGEN RECEPTOR; FULVESTRANT; MYELIN BASIC PROTEIN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; PRODRUG; TAMOXIFEN;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL COUNT; CELL LEVEL; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; NERVE CELL DIFFERENTIATION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; NEURAL STEM CELL;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; FLUORESCENT ANTIBODY TECHNIQUE; NEURAL STEM CELLS; OLIGODENDROGLIA; PRODRUGS; RATS; TAMOXIFEN;

EID: 84957595070     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.01.026     Document Type: Article

References (56)

1. Abney E.R., Williams B.P., Raff M.C. Tracing the development of oligodendrocytes from precursor cells using monoclonal antibodies, fluorescence-activated cell sorting, and cell culture. Dev Biol 1983, 100:166-171.
2. Ahmad A., Shahabuddin S., Sheikh S., Kale P., Krishnappa M., Rane R.C., Ahmad I. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 2010, 88:814-817.
3. Arevalo M.A., Santos-Galindo M., Lagunas N., Azcoitia I., Garcia-Segura L.M. Selective estrogen receptor modulators as brain therapeutic agents. J Mol Endocrinol 2011, 46:R1-R9.
4. Baas D., Legrand C., Samarut J., Flamant F. Persistence of oligodendrocyte precursor cells and altered myelination in optic nerve associated to retina degeneration in mice devoid of all thyroid hormone receptors. Proc Natl Acad Sci U S A 2002, 99:2907-2911.
5. Baracskay K.L., Kidd G.J., Miller R.H., Trapp B.D. NG2-positive cells generate A2B5-positive oligodendrocyte precursor cells. Glia 2007, 55:1001-1010.
6. Barres B.A., Lazar M.A., Raff M.C. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 1994, 120:1097-1108.
7. Bebo B.F., Dehghani B., Foster S., Kurniawan A., Lopez F.J., Sherman L.S. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia 2009, 57:777-790.
8. Billon N., Tokumoto Y., Forrest D., Raff M. Role of thyroid hormone receptors in timing oligodendrocyte differentiation. Dev Biol 2001, 235:110-120.
9. Boulware S.B., Christensen L.A., Thames H., Coghlan L., Vasquez K.M., Finch R.A. Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog 2014, 53:744-752.
10. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758.
11. Calza L., Fernandez M., Giuliani A., Aloe L., Giardino L. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 2002, 99:3258-3263.
12. Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997, 45:607-617.
13. Codega P., Silva-Vargas V., Paul A., Maldonado-Soto A.R., Deleo A.M., Pastrana E., Doetsch F. Prospective identification and purification of quiescent adult neural stem cells from their in vivo niche. Neuron 2014, 82:545-559.
14. Crawford D.K., Mangiardi M., Song B., Patel R., Du S., Sofroniew M.V., Voskuhl R.R., Tiwari-Woodruff S.K. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 2010, 133:2999-3016.
15. Day R., Ganz P.A., Costantino J.P., Cronin W.M., Wickerham D.L., Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999, 17:2659-2669.
16. Deshmukh V.A., Tardif V., Lyssiotis C.A., Green C.C., Kerman B., Kim H.J., Padmanabhan K., Swoboda J.G., Ahmad I., Kondo T., Gage F.H., Theofilopoulos A.N., Lawson B.R., Schultz P.G., Lairson L.L. A regenerative approach to the treatment of multiple sclerosis. Nature 2013, 502:327-332.
17. Dwosh E., Guimond C., Duquette P., Sadovnick A.D. The interaction of MS and pregnancy: a critical review. Int MS J 2003, 10:38-42.
18. Fancy S.P., Chan J.R., Baranzini S.E., Franklin R.J., Rowitch D.H. Myelin regeneration: a recapitulation of development?. Annu Rev Neurosci 2011, 34:21-43.
19. Fernandez M.F., Aguilar-Garduno C., Molina-Molina J.M., Arrebola J.P., Olea N. The total effective xenoestrogen burden, a biomarker of exposure to xenoestrogen mixtures, is predicted by the (anti)estrogenicity of its components. Reprod Toxicol 2008, 26:8-12.
20. Franklin R.J., Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008, 9:839-855.
21. Girolamo F., Strippoli M., Errede M., Benagiano V., Roncali L., Ambrosi G., Virgintino D. Characterization of oligodendrocyte lineage precursor cells in the mouse cerebral cortex: a confocal microscopy approach to demyelinating diseases. Ital J Anat Embryol 2010, 115:95-102.
22. Guptarak J., Wiktorowicz J.E., Sadygov R.G., Zivadinovic D., Paulucci-Holthauzen A.A., Vergara L., Nesic O. The cancer drug tamoxifen: a potential therapeutic treatment for spinal cord injury. J Neurotrauma 2014, 31:268-283.
23. Guzman C.B., Deighton-Collins S., Martinez A., Kleerekoper M., Zhao C., Benjamins J.A., Skafar D.F. Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line. Neuro Endocrinol Lett 2005, 26:526-532.
24. Hoskins J.M., Carey L.A., McLeod H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009, 9:576-586.
25. Huang J.K., Fancy S.P., Zhao C., Rowitch D.H., Ffrench-Constant C., Franklin R.J. Myelin regeneration in multiple sclerosis: targeting endogenous stem cells. Neurotherapeutics 2011, 8:650-658.
26. Iusuf D., Teunissen S.F., Wagenaar E., Rosing H., Beijnen J.H., Schinkel A.H. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther 2011, 337:710-717.
27. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., Desta Z., Flockhart D.A., Skaar T.C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004, 85:151-159.
28. Jokela T., Vainio S. Conditional tamoxifen Cre induced mutagenesis in the embryonic kidney in organ culture. Genesis 2007, 45:757-761.
29. Karki P., Webb A., Smith K., Lee K., Son D.S., Aschner M., Lee E. CAMP response element-binding protein (CREB) and nuclear factor kappaB mediate the tamoxifen-induced up-regulation of glutamate transporter 1 (GLT-1) in rat astrocytes. J Biol Chem 2013, 288:28975-28986.
30. Kawai K., Itoh T., Itoh A., Horiuchi M., Wakayama K., Bannerman P., Garbern J.Y., Pleasure D., Lindsten T. Maintenance of the relative proportion of oligodendrocytes to axons even in the absence of BAX and BAK. Eur J Neurosci 2009, 30:2030-2041.
31. Khalaj A.J., Yoon J., Nakai J., Winchester Z., Moore S.M., Yoo T., Martinez-Torres L., Kumar S., Itoh N., Tiwari-Woodruff S.K. Estrogen receptor (ER) beta expression in oligodendrocytes is required for attenuation of clinical disease by an ERbeta ligand. Proc Natl Acad Sci U S A 2013, 110:19125-19130.
32. Lien E.A., Solheim E., Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991, 51:4837-4844.
33. Lim Y.C., Desta Z., Flockhart D.A., Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005, 55:471-478.
34. Mei F., Fancy S.P., Shen Y.A., Niu J., Zhao C., Presley B., Miao E., Lee S., Mayoral S.R., Redmond S.A., Etxeberria A., Xiao L., Franklin R.J., Green A., Hauser S.L., Chan J.R. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med 2014, 20:954-960.
35. Najm F.J., et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature 2015, 522:216-220.
36. O'Brian C.A., Liskamp R.M., Solomon D.H., Weinstein I.B. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985, 45:2462-2465.
37. O'Brian C.A., Housey G.M., Weinstein I.B. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 1988, 48:3626-3629.
38. Okada M., Murase K., Makino A., Nakajima M., Kaku T., Furukawa S., Furukawa Y. Effects of estrogens on proliferation and differentiation of neural stem/progenitor cells. Biomed Res 2008, 29:163-170.
39. Okada M., Makino A., Nakajima M., Okuyama S., Furukawa S., Furukawa Y. Estrogen stimulates proliferation and differentiation of neural stem/progenitor cells through different signal transduction pathways. Int J Mol Sci 2010, 11:4114-4123.
40. Okada H., Okamoto R., Tsuzuki T., Tsuji S., Yasuda K., Kanzaki H. Progestins inhibit estradiol-induced vascular endothelial growth factor and stromal cell-derived factor 1 in human endometrial stromal cells. Fertil Steril 2011, 96:786-791.
41. Paige L.A., Christensen D.J., Gron H., Norris J.D., Gottlin E.B., Padilla K.M., Chang C.Y., Ballas L.M., Hamilton P.T., McDonnell D.P., Fowlkes D.M. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci U S A 1999, 96:3999-4004.
42. Platania P., Laureanti F., Bellomo M., Giuffrida R., Giuffrida-Stella A.M., Catania M.V., Sortino M.A. Differential expression of estrogen receptors alpha and beta in the spinal cord during postnatal development: localization in glial cells. Neuroendocrinology 2003, 77:334-340.
43. Rajasekharan S., Baker K.A., Horn K.E., Jarjour A.A., Antel J.P., Kennedy T.E. Netrin 1 and Dcc regulate oligodendrocyte process branching and membrane extension via Fyn and RhoA. Development 2009, 136:415-426.
44. Rosenzweig S., Carmichael S.T. The axon-glia unit in white matter stroke: mechanisms of damage and recovery. Brain Res 2015, 1623:123-134.
45. Schoemans R., Aigrot M.S., Wu C., Maree R., Hong P., Belachew S., Josse C., Lubetzki C., Bours V. Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. J Inherit Metab Dis 2010, 33:113-120.
46. Shao B., Cheng Y., Jin K. Estrogen, neuroprotection and neurogenesis after ischemic stroke. Curr Drug Targets 2012, 13:188-198.
47. Sperber B.R., McMorris F.A. Fyn tyrosine kinase regulates oligodendroglial cell development but is not required for morphological differentiation of oligodendrocytes. J Neurosci Res 2001, 63:303-312.
48. Tokumoto Y.M., Tang D.G., Raff M.C. Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein. EMBO J 2001, 20:5261-5268.
49. Waters E.A., Cronin K.A., Graubard B.I., Han P.K., Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010, 19:443-446.
50. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002, 125:338-349.
51. Wu X., Hawse J.R., Subramaniam M., Goetz M.P., Ingle J.N., Spelsberg T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009, 69:1722-1727.
52. Xiao L., Guo D., Hu C., Shen W., Shan L., Li C., Liu X., Yang W., Zhang W., He C. Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination. Glia 2012, 60:1037-1052.
53. Yildiz A., Guleryuz S., Ankerst D.P., Ongur D., Renshaw P.F. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008, 65:255-263.
54. Zarate C.A., Singh J.B., Carlson P.J., Quiroz J., Jolkovsky L., Luckenbaugh D.A., Manji H.K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007, 9:561-570.
55. Zhang Z., Cerghet M., Mullins C., Williamson M., Bessert D., Skoff R. Comparison of in vivo and in vitro subcellular localization of estrogen receptors alpha and beta in oligodendrocytes. J Neurochem 2004, 89:674-684.
56. Zheng A., Kallio A., Harkonen P. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 2007, 148:2764-2777.